<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00435292</url>
  </required_header>
  <id_info>
    <org_study_id>LOA-03P</org_study_id>
    <nct_id>NCT00435292</nct_id>
  </id_info>
  <brief_title>Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi Center Study of Flavocoxid ( Limbrel) vs Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Primus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Primus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo controlled parallel group, multi center study in subjects
      with moderate-severe osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double blind, placebo controlled, parallel group, multi-center
      study in subjects with moderate-severe OA. Subjects will be randomized to receive flavocoxid
      250 mg bid, flavocoxid 500 mg bid, naproxen 500 mg bid or placebo in a 2:2:2:1 ratio.
      Subjects will take study materials twice daily for twelve (12) weeks. After the 12 week visit
      subjects in the placebo arm will be re-randomized to the two flavocoxid arms. All subjects
      will then continue on the study for an additional 12 weeks.

      Subjects will keep a diary noting date of onset of symptom change (better or worse), adverse
      events and cost of all aspects of medical care related directly or indirectly to
      osteoarthritis.

      Laboratory studies for inflammatory markers will be drawn and archived at baseline and at the
      12 week visit. In addition, a subgroup of subjects will have arthrocenteses performed at
      baseline and the 12 week visit and the synovial fluid archived for study of intra-articular
      inflammatory markers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>flavocoxid 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flavonoid mixture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flavocoxid 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flavonoid mixture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nonsteroidal antiinflammatory drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>nonsteroidal anti-inflammatory drug</description>
    <arm_group_label>naproxen</arm_group_label>
    <other_name>naprosyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>flavocoxid 250 mg</intervention_name>
    <description>flavonoid mixture</description>
    <arm_group_label>flavocoxid 250 mg</arm_group_label>
    <other_name>Limbrel 250 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>flavocoxid 500 mg</intervention_name>
    <description>flavonoid mixture</description>
    <arm_group_label>flavocoxid 500 mg</arm_group_label>
    <other_name>limbrel 500 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  OA of the Knee

          -  K-L Grade 2-3

          -  Positive response to NSAIDS

        Exclusion Criteria:

          -  K-L grade 1 0r 4 OA of the knee

          -  History of GI Bleed within past 5 years

          -  Chronic bleeding disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Levy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Primus Pharmaceuticals,Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Kivitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Primus Pharmaceuticals, Inc</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2007</study_first_submitted>
  <study_first_submitted_qc>February 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2007</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

